Rigel Pharmaceuticals, Inc.

Investors News & Events Contact Us
  • Home
  • Who We Are
    • Company Overview
    • Management Team
    • Board of Directors
    • Partners
  • Pipeline
    • Pipeline
      • Clinical Trials
      • Investigator Sponsored Research
      • Expanded Access Policy
    • Proprietary Programs
      • IRAK1/4
      • RIPK1
      • COVID-19
    • Partnered Programs
      • BerGenBio
      • Daiichi-Sankyo
      • Forma
      • Grifols
      • Kissei
      • Lilly
      • Medison
      • Knight
  • Products
  • Join Our Team
    • Life at Rigel
    • Our Values
    • Benefits
    • Current Openings
  • Investors
  • News & Events
  • Contact Us

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
    • Email Alerts
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • FAQ
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Analyst Coverage
  • Governance
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Press Releases
  • Events & Presentations
  • Email Alerts
Nov 24, 2014 7:30am EST

Rigel Announces Executive Management Changes

Nov 04, 2014 7:30am EST

Rigel Announces Third Quarter 2014 Financial Results

Aug 13, 2014 7:30am EDT

R348 Did Not Meet Endpoints in Phase 2 Dry Eye Study

Aug 05, 2014 7:30am EDT

Rigel Announces Second Quarter 2014 Financial Results

Jul 16, 2014 7:30am EDT

Rigel Initiates Phase 3 Studies of Fostamatinib in ITP

May 29, 2014 7:30am EDT

Rigel to Present at Jefferies 2014 Global Healthcare Conference

May 07, 2014 7:30am EDT

Rigel Announces First Quarter 2014 Financial Results

Apr 30, 2014 7:30am EDT

Rigel Announces Webcast of Investor Day on May 6, 2014

Mar 06, 2014 7:30am EST

Rigel Announces Publication of R118 AMPK Activator Research

Mar 04, 2014 7:30am EST

Rigel Announces Fourth Quarter and Year End 2013 Financial Results

  • Previous
  • 1…
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • …37
  • Next
RSS
  • Email Alerts
  • RSS News Feed
Terms of Use Privacy Policy Your Cookie Preferences

© 2023 Rigel Pharmaceuticals, Inc. All Rights Reserved.

TAVALISSE, TAVLESSE, REZLIDHIA, RIGEL and the Rigel arc logo are registered trademarks of Rigel Pharmaceuticals, Inc.

Facebook Twitter Linkedin